Stock Track | ESSEX BIO-TECH Shares Plunge 10% After Reporting Weak H1 Results

Stock Track08-27

Shares of ESSEX BIO-TECH (HKG:1061) plummeted as much as 9.66% in intraday trading on Monday, following the release of the company's financial results for the first half of 2024.

The Hong Kong-listed biopharmaceutical firm reported a 7.3% year-over-year decline in profit to HK$157.4 million for the six months ended June 30th. Revenue also fell sharply, decreasing by 9.8% to HK$811.6 million compared to the same period last year.

While ESSEX BIO-TECH raised its interim dividend payout to HK$0.06 per share from HK$0.045 a year ago, the weaker financial performance appeared to weigh heavily on investor sentiment. The company's earnings per share declined to HK$0.269 from HK$0.288 in the first half of 2023.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment